^
Association details:
| Biomarker: | EGFR exon 21 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy
Published date:
07/12/2021
Excerpt:
...81 included patients had driver gene mutations, including 69 EGFR mutation (85.2%), 28 classical exon 19 deletions (34.6%), 17 exon 21 mutations (21%). In addition, there were nine ALK mutations (11.1%), one ROS (1.2%), and two HER2 mutation (2.5%)....The median progression-free survival of involved 81 patients was 13.87 months (95% confidence interval (CI): 11.66–16.08), and the median survival was 41.47 months (95%CI: 20.11–62.83)....TKIs are a viable option for mutant stage III unresectable NSCLC patients who have achieved good clinical benefit from TKI....
DOI:
https://doi.org/10.3389/fonc.2021.692703
